The question of what products and processes are eligible for patent protection, and in particular the scope of the exception for laws of nature, has been the subject of recent scrutiny in the Supreme Court and Federal Circuit. The panel will address the latest developments in patentable subject matter law regarding the patenting of isolated DNA molecules. Panelists will present recent case examples such as the Myriad Genetics case, Mayo Collaborative Services vs Prometheus Labs., Inc. case, and related developments in the courts and Congress that could affect the biotechnology industry.

Learning Objectives:

  • Review recent developments in the law of patentable subject matter
  • Discuss BIO’s leadership role on the issue of patentable subject matter
  • Engage in a spirited discussion of the implications of recent court decisions

Ability Level: All

Session ID: 1972

myBIO Chatter

Speakers (3)

contact_9828 Hon. Arthur Gajarsa (Retired) Former Senior Judge U.S. Court of Appeals for the Federal Circuit
contact_8203 Mary Till Legal Advisor United States Patent and Trademark Office
contact_5934 Seth Waxman Partner WilmerHale

Moderators (1)

contact_5935 Mark Fleming Partner WilmerHale